- ¥1tn
- ¥997bn
- ¥497bn
Brief: Kyowa Kirin Announces Top-Line Data From Rocatinlimab Phase 3 Rocket Horizon Trial
Brief: Kyowa Kirin To End Distribution Of Fareston (Toremefine) In United States
Announcement Regarding Restructuring Of Apac Region Business And Change In A Specified Subsidiary
Brief: Kyowa Kirin Announces Board Approval For Construction Of New Biologics Manufacturing Plant In Sanford, NC
Announces Result Of Share Buyback For May
Table: Kyowa Kirin -Q1 group results (IFRS)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
Kyowa Kirin's gene therapy most expensive US drug with $4.3 mln price tag
US approves first gene therapy for children with rare genetic disease (updated)
US approves first gene therapy for rare genetic disease
Announces Result Of Share Buyback For Feb 13-29
BridgeBio rises on $100 mln license deal for drug development in Japan
To Buy Back Up To 3.2% Of Shares Worth 40 Billion Yen
Table: Kyowa Kirin -2023 parent results
Table: Kyowa Kirin -2023 group results (IFRS)
Brief: Kyowa Kirin Announces First Patient Enrolled In The Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops In Patients With Diabetic Macular Edema
Brief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Table: Kyowa Kirin -9-MTH group results (IFRS)